Pfizer Intrinsic Value
Pfizer (PFIZER) median intrinsic value is ₹1849.04 from 9 valuation models (range ₹1387–₹3474), vs current price ₹4622.60 — -60.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Also explore PFIZER share price charts to track price trends across different timeframes.
PFIZER Valuation Methods Summary — DCF, Graham Number & P/E
Pfizer intrinsic value across 9 models vs current price ₹4622.60 — upside/downside and value range per method. For current market price and key ratios, visit Pfizer share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹3474.24 | ₹2779.39 - ₹4169.09 | -24.8% | EPS: ₹157.92, Sector P/E: 22x |
| Book Value Method | asset | ₹1827.39 | ₹1644.65 - ₹2010.13 | -60.5% | Book Value/Share: ₹913.70, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1386.78 | ₹1248.10 - ₹1525.46 | -70.0% | Revenue/Share: ₹547.83, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1858.70 | ₹1672.83 - ₹2044.57 | -59.8% | EBITDA: ₹855.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1849.04 | ₹1479.23 - ₹2218.85 | -60.0% | CF Growth: 11.5%, Discount: 15% |
| PEG Ratio Method | growth | ₹1386.78 | ₹1248.10 - ₹1525.46 | -70.0% | EPS Growth: 4.2%, Fair P/E: 3.4x |
| Growth Adjusted P/E | growth | ₹2351.37 | ₹2116.23 - ₹2586.51 | -49.1% | Revenue Growth: -1.5%, Adj P/E: 14.9x |
| ROE Based Valuation | profitability | ₹2311.30 | ₹2080.17 - ₹2542.43 | -50.0% | ROE: 17.1%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹1801.82 | ₹1621.64 - ₹1982.00 | -61.0% | EPS: ₹157.92, BVPS: ₹913.70 |
PFIZER Intrinsic Value vs Market Price — All Valuation Models
Pfizer fair value range ₹1387–₹3474 vs current market price ₹4622.60 across 9 valuation models. Browse PFIZER balance sheet details for revenue, profit, balance sheet and cash flow data.
PFIZER Intrinsic Value Analysis — Undervalued or Overvalued?
Pfizer median intrinsic value ₹1849.04, current price ₹4622.60 — Trading Above Calculated Value by 60.0%, margin of safety -100.0%.
What is the intrinsic value of PFIZER?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Pfizer (PFIZER) is ₹1849.04 (median value). With the current market price of ₹4622.60, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹1386.78 to ₹3474.24, indicating ₹1386.78 - ₹3474.24.
Is PFIZER undervalued or overvalued?
Based on our multi-method analysis, Pfizer (PFIZER) appears to be trading above calculated value by approximately 60.0%.
PFIZER Financial Health — Key Ratios vs Industry Benchmarks
Pfizer financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 41.34 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 17.1% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 34.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.51x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
PFIZER Cash Flow Quality — Operating & Free Cash Flow
Pfizer operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹660 Cr | ₹625 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹257 Cr | ₹257 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹356 Cr | ₹338 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹667 Cr | ₹380 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹427 Cr | ₹193 Cr | Positive Free Cash Flow | 7/10 |